Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin

International Immunology
H NotoK Imai

Abstract

MUC1 is a highly immunogenic epithelial mucin and serves as a tumor-associated antigen in breast, pancreatic and ovarian carcinomas. We previously reported the expression of MUC1 on myeloma cells and the establishment of an HLA-unrestricted cytotoxic T lymphocyte (CTL) line TN that recognized MUC1 from peripheral blood mononuclear cells in a multiple myeloma patient. In this study, we attempted to induce such CTL from six other multiple myeloma patients consecutively in order to show that the induction of the CTL line TN had not resulted from some idiosyncrasy of the first patient. Bone marrow mononuclear cells were used to induce CTL, because they contain myeloma cells that might stimulate the autologous lymphocytes. Bulk CTL lines were induced from two out of six patients. The CTL line TS was CD8+ cell dominant and KY was CD4+ cell dominant. Both CTL lines lysed MUC1+ myeloma and breast carcinoma cell lines. The cytotoxicity of the CTL lines was inhibited by anti-CD3, anti-alpha beta TCR and anti-MUC1 mAb. It was also inhibited by a MUC1 transfectant, but not by a mock transfectant in cold target inhibition assays. MUC1 was transfected into a human colonic carcinoma cell line. The reactivity of anti-MUC1 core protein mAb and ...Continue Reading

Citations

Apr 6, 2001·International Journal of Cancer. Journal International Du Cancer·L StaibD Herlyn
Apr 12, 2002·Journal of Clinical Laboratory Analysis·Yukihiko SatohYuji Hinoda
Dec 24, 2005·Journal of Cancer Research and Clinical Oncology·Brigitte GückelDiethelm Wallwiener
Dec 21, 2002·British Journal of Haematology·Catherine Pellat-Deceunynck
Mar 6, 2003·Reviews in Clinical and Experimental Hematology·Roberto Bellucci, Jerome Ritz
Dec 17, 2009·The Cancer Journal·Qing Yi
Oct 16, 2001·Drugs & Aging·S Matzku, M Zöller
Jun 1, 2012·Clinical & Developmental Immunology·Ivetta DanyleskoArnon Nagler
Jul 24, 2004·Critical Reviews in Clinical Laboratory Sciences·Stephan E BaldusFranz-Georg Hanisch
Dec 25, 2003·Leukemia & Lymphoma·Daniel M Y SzeBarbara Fazekas de St Groth
Oct 3, 2006·British Journal of Haematology·Silvie CloosenGerard M J Bos
Jan 10, 2013·Scandinavian Journal of Immunology·A Anandkumar, H Devaraj
Mar 20, 2013·BioMed Research International·David RouloisJean-François Fonteneau
Apr 26, 2003·Blood·Toshiaki HayashiKenneth C Anderson
Jul 20, 2002·Blood·Maurizio Chiriva-InternatiSeah H Lim
Dec 23, 1999·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·T KokuboY Kobayashi
Aug 18, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·J StöcklW Knapp
Mar 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kwong-Yok TsangJeffrey Schlom
Feb 10, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthias GrubeErnst Holler
Nov 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Taichi AzumaMasaki Yasukawa
Oct 20, 1999·Blood Reviews·G Cook, J D Campbell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.